560 related articles for article (PubMed ID: 32729887)
21. Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk.
Ahern CH; Shih YC; Dong W; Parmigiani G; Shen Y
Br J Cancer; 2014 Oct; 111(8):1542-51. PubMed ID: 25137022
[TBL] [Abstract][Full Text] [Related]
22. Cost-Effectiveness of Population-Based Multigene Testing for Breast and Ovarian Cancer Prevention.
Guo F; Adekanmbi V; Hsu CD; Berenson AB; Kuo YF; Shih YT
JAMA Netw Open; 2024 Feb; 7(2):e2356078. PubMed ID: 38353949
[TBL] [Abstract][Full Text] [Related]
23. Breast MRI screening for average-risk women: A monte carlo simulation cost-benefit analysis.
Mango VL; Goel A; Mema E; Kwak E; Ha R
J Magn Reson Imaging; 2019 Jun; 49(7):e216-e221. PubMed ID: 30632645
[TBL] [Abstract][Full Text] [Related]
24. The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation.
Robertson C; Arcot Ragupathy SK; Boachie C; Dixon JM; Fraser C; Hernández R; Heys S; Jack W; Kerr GR; Lawrence G; MacLennan G; Maxwell A; McGregor J; Mowatt G; Pinder S; Ternent L; Thomas RE; Vale L; Wilson R; Zhu S; Gilbert FJ
Health Technol Assess; 2011 Sep; 15(34):v-vi, 1-322. PubMed ID: 21951942
[TBL] [Abstract][Full Text] [Related]
25. Assessing the Cost-Effectiveness of Updated Breast Cancer Screening Guidelines for Average-Risk Women.
Tina Shih YC; Dong W; Xu Y; Shen Y
Value Health; 2019 Feb; 22(2):185-193. PubMed ID: 30711063
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.
Guzauskas GF; Garbett S; Zhou Z; Spencer SJ; Smith HS; Hao J; Hassen D; Snyder SR; Graves JA; Peterson JF; Williams MS; Veenstra DL
JAMA Netw Open; 2020 Oct; 3(10):e2022874. PubMed ID: 33119106
[TBL] [Abstract][Full Text] [Related]
27. Incorporating Baseline Breast Density When Screening Women at Average Risk for Breast Cancer : A Cost-Effectiveness Analysis.
Shih YT; Dong W; Xu Y; Etzioni R; Shen Y
Ann Intern Med; 2021 May; 174(5):602-612. PubMed ID: 33556275
[TBL] [Abstract][Full Text] [Related]
28. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density.
Riedl CC; Luft N; Bernhart C; Weber M; Bernathova M; Tea MK; Rudas M; Singer CF; Helbich TH
J Clin Oncol; 2015 Apr; 33(10):1128-35. PubMed ID: 25713430
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model.
Pashayan N; Morris S; Gilbert FJ; Pharoah PDP
JAMA Oncol; 2018 Nov; 4(11):1504-1510. PubMed ID: 29978189
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
Kemp Z; Turnbull A; Yost S; Seal S; Mahamdallie S; Poyastro-Pearson E; Warren-Perry M; Eccleston A; Tan MM; Teo SH; Turner N; Strydom A; George A; Rahman N
JAMA Netw Open; 2019 May; 2(5):e194428. PubMed ID: 31125106
[TBL] [Abstract][Full Text] [Related]
31. MRI screening for breast cancer in women with familial or genetic predisposition: design of the Dutch National Study (MRISC).
Kriege M; Brekelmans CT; Boetes C; Rutgers EJ; Oosterwijk JC; Tollenaar RA; Manoliu RA; Holland R; de Koning HJ; Klijn JG
Fam Cancer; 2001; 1(3-4):163-8. PubMed ID: 14574173
[TBL] [Abstract][Full Text] [Related]
32. [Choices for women at risk of hereditary breast cancer].
Saadatmand S; Obdeijn IM; Koppert LB; Tilanus-Linthorst M
Ned Tijdschr Geneeskd; 2013; 157(43):A6625. PubMed ID: 24152366
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of annual versus biennial screening mammography for women with high mammographic breast density.
Pataky R; Ismail Z; Coldman AJ; Elwood M; Gelmon K; Hedden L; Hislop G; Kan L; McCoy B; Olivotto IA; Peacock S
J Med Screen; 2014 Dec; 21(4):180-8. PubMed ID: 25186116
[TBL] [Abstract][Full Text] [Related]
34. Dynamic contrast-enhanced magnetic resonance imaging for risk-stratified screening in women with BRCA mutations or high familial risk for breast cancer: are we there yet?
Whitaker KD; Sheth D; Olopade OI
Breast Cancer Res Treat; 2020 Sep; 183(2):243-250. PubMed ID: 32621252
[TBL] [Abstract][Full Text] [Related]
35. Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women.
Taneja C; Edelsberg J; Weycker D; Guo A; Oster G; Weinreb J
J Am Coll Radiol; 2009 Mar; 6(3):171-9. PubMed ID: 19248993
[TBL] [Abstract][Full Text] [Related]
36. Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features.
Gilbert FJ; Warren RM; Kwan-Lim G; Thompson DJ; Eeles RA; Evans DG; Leach MO;
Radiology; 2009 Aug; 252(2):358-68. PubMed ID: 19703879
[TBL] [Abstract][Full Text] [Related]
37. Long-Term Outcomes and Cost-Effectiveness of Breast Cancer Screening With Digital Breast Tomosynthesis in the United States.
Lowry KP; Trentham-Dietz A; Schechter CB; Alagoz O; Barlow WE; Burnside ES; Conant EF; Hampton JM; Huang H; Kerlikowske K; Lee SJ; Miglioretti DL; Sprague BL; Tosteson ANA; Yaffe MJ; Stout NK
J Natl Cancer Inst; 2020 Jun; 112(6):582-589. PubMed ID: 31503283
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of digital mammography screening before the age of 50 in The Netherlands.
Sankatsing VD; Heijnsdijk EA; van Luijt PA; van Ravesteyn NT; Fracheboud J; de Koning HJ
Int J Cancer; 2015 Oct; 137(8):1990-9. PubMed ID: 25895135
[TBL] [Abstract][Full Text] [Related]
39. The cost-effectiveness of adding tomosynthesis to mammography-based breast cancer screening: an economic analysis.
Cressman S; Mar C; Sam J; Kan L; Lohrisch C; Spinelli JJ
CMAJ Open; 2021; 9(2):E443-E450. PubMed ID: 33888549
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
